Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
Peptide longevity stack claims — review
The longevity-stack space typically combines pineal peptides (Epitalon), mitochondrial-derived peptides (MOTS-c, Humanin, SS-31), copper peptides (GHK-Cu), and NAD+ precursors (NMN / NR). This page covers what they have in common: heavy marketing, mechanistic plausibility, and a near-complete absence of human longevity-outcome trial evidence.
Common longevity-stack claims
- “Reverses biological ageing”
- “Lengthens telomeres”
- “Restores mitochondrial function”
- “Adds 10-20 years of healthspan”
The honest picture
Mechanistic-cell-and-rodent data exist for most longevity-stack peptides. Human Phase 3 outcome trials for any longevity endpoint do not. Russian observational data for Epitalon has not been independently replicated in Western trials.
The evidence-based UK longevity intervention
- Regular exercise (aerobic + resistance) — the strongest single intervention.
- Mediterranean-style diet pattern.
- Smoking cessation and alcohol moderation.
- Sleep adequacy and quality.
- Routine NHS Health Check (free, every 5 years for ages 40-74).
- Cancer screening uptake — the highest-impact longevity intervention available in the UK.
Frequently asked questions
- Do peptide longevity stacks extend human lifespan?
- No randomised human trial demonstrates that any peptide combination extends human lifespan. Mechanistic stories abound; outcome evidence is absent.
- What is the strongest-evidence longevity intervention?
- Regular aerobic + resistance exercise, Mediterranean-style diet, adequate sleep, smoking cessation, alcohol moderation, and routine cancer screening. None of these are peptides.
- Are these stacks legal in the UK?
- Most longevity-stack peptides (Epitalon, MOTS-c, Humanin, injectable GHK-Cu) are unlicensed in the UK. Sale with longevity claims engages UK medicines regulation.
- What about NMN / NR supplements?
- Oral NMN and NR raise NAD+ precursor levels modestly in human studies; clinical-outcome benefit (longevity, healthspan, disease prevention) is not yet demonstrated.
- What is the cancer-promotion concern?
- Sustained telomerase activation (Epitalon claim) and growth-factor pathway activation have theoretical oncologic concerns. Long-term human surveillance does not exist for any peptide longevity stack.